Cagrilintide

Cagrilintide

Cagrilintide is a long-acting synthetic amylin analog acting on CALCR/RAMP receptor complexes, distinct from GLP-1 agonists, and currently under Phase 3 investigation for appetite regulation, weight reduction, and management of obesity and type 2 diabetes. Licensed practitioners who want to buy Cagrilintide can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. Browse this page to learn more about Cagrilintide and its research applications through the overview and FAQ sections below.

Cagrilintide: Legal Status, Regulatory Context & Classification

Cagrilintide is a long-acting synthetic amylin analog derived from islet amyloid polypeptide (IAPP) and developed by Novo Nordisk [5]. It has completed its primary Phase 3a investigations through the REDEFINE clinical trial program, evaluated both as monotherapy and in a fixed-dose combination with Semaglutide under the CagriSema protocol [3][4]. Regulatory applications for weight management were submitted to the US FDA in December 2025.

Primary research applications include appetite regulation, weight reduction, and management of obesity and type 2 diabetes [1][3][4]. Cagrilintide is not a GLP-1 receptor agonist; it targets amylin receptor pathways involved in satiety signaling and gastric emptying [5]. All major trials incorporated structured lifestyle interventions alongside the peptide, including caloric restriction, behavioral counseling, and exercise protocols [1][3][4].

Regulatory status as of mid 2026:

• United States: Not yet FDA-approved for commercial prescribing or routine clinical use; a regulatory application was submitted in December 2025, and review is ongoing
  European Union: Not EMA-approved; regulatory submissions are anticipated following the completed REDEFINE Phase 3 program [3][4]
• European Union: Not EMA-approved; regulatory submissions are anticipated following the completed REDEFINE Phase 3 program
• Australia: Not TGA-approved; availability restricted to investigational or research contexts depending on jurisdiction
• General: No approved prescribing information currently exists for Cagrilintide dosage, long-term safety management, or population-specific treatment protocols

Clinicians evaluating investigational metabolic therapies should verify jurisdiction-specific guidance before incorporating Cagrilintide into research protocol discussions.

How Cagrilintide Works: Amylin Mechanism & Half Life

Cagrilintide activates amylin receptor complexes, specifically CALCR/RAMP1 and CALCR/RAMP3 pathways, in hypothalamic and brainstem centers involved in appetite regulation [5]. This mechanism is distinct from GLP-1 receptor agonism and directly addresses a common point of confusion when comparing Cagrilintide with Semaglutide or Tirzepatide.

Key mechanistic features supported by preclinical and Phase 2 and 3 human data include:

• Satiety Signaling: Receptor activation in appetite-regulating brain centers enhances satiety and reduces caloric intake [1][5]
• Gastric Emptying: Slows postprandial gastric motility, prolonging fullness after meals and contributing to changes in body weight [1][5]
• Glucagon Suppression: Reduces postprandial glucagon secretion without directly stimulating insulin, relevant to obesity and type 2 diabetes subgroups [2]
• Central Appetite Modulation: Preclinical and translational evidence suggests activity in the area postrema and nucleus accumbens, potentially reducing food-reward signaling via pathways distinct from GLP-1’s primary gut-brain satiety arc [5]
• Cagrilintide Half-life: Approximately seven days, engineered for stable plasma concentrations and enabling once-weekly subcutaneous administration in Phase 3 investigations [5]

Cagrilintide Benefits & Weight Loss Data

Human clinical trial data have demonstrated meaningful weight reduction and metabolic effects across both monotherapy and combination therapy settings. All efficacy findings below are trial-specific and should be interpreted within their evidence context.

Monotherapy (Phase 2)

• A controlled Phase 2 study evaluating weekly doses up to 4.5 mg reported approximately 10.8% mean body weight reduction over 26 weeks (Lau et al., The Lancet, 2021) [1]
• Investigators noted that broader, longer-duration studies were necessary before definitive clinical conclusions could be drawn [1]

CagriSema Combination (Phase 3 REDEFINE Program)

Rather than relying on early projections, the therapeutic profile of the CagriSema combination (2.4 mg cagrilintide / 2.4 mg semaglutide) is now established by landmark Phase 3a data published in the New England Journal of Medicine (2025):

• REDEFINE 1 (obesity without type 2 diabetes): In adults with overweight or obesity, CagriSema achieved a statistically significant mean body weight reduction of 20.4% at 68 weeks, rising to 22.7% among participants with full treatment adherence (Garvey et al., NEJM, 2025) [3]. This places the combination among the highest-efficacy weight loss interventions evaluated to date [3].
• REDEFINE 2 (obesity with type 2 diabetes): Davies et al. (NEJM, 2025) reported a 13.7% mean body weight reduction alongside profound glycemic improvements in adults presenting with both obesity and type 2 diabetes, with 73.5% of participants reaching an HbA1c target of 6.5% or lower (15.7% weight reduction with full treatment adherence) [4].
• Additive Efficacy: These outcomes confirm the complementary nature of combining amylin receptor and GLP-1 receptor pathways, targeting peripheral and central satiety signaling simultaneously to produce effects that neither agent alone achieves [3][4].

Cagrilintide Starting Dose, Administration & Storage

No FDA-approved prescribing protocol exists for Cagrilintide. All dosing information below is derived from clinical trial frameworks and should not be interpreted as validated clinical guidance.

Administration

• Cagrilintide starting dose:16 mg once weekly via subcutaneous injection [1][3]
• Titration: Gradual escalation over approximately 16 weeks toward target doses such as 2.4 mg in CagriSema protocols [2]; slow titration is intended to reduce gastrointestinal tolerability concerns [1]
• Injection sites: Abdomen, thigh, or upper arm with rotation; once-weekly timing consistent across investigational protocols [1][3]

Storage

• Refrigerate at 2–8°C; protect from direct light; do not freeze
• Professionals evaluating where to order Cagrilintide for research use should verify purity documentation, storage compliance, and manufacturing handling standards before sourcing

Cagrilintide Side Effects & Safety Profile

Human Phase 2 and Phase 3 studies suggest Cagrilintide side effects are generally consistent with gastrointestinal class effects associated with amylin analog and GLP-1 pathway therapies [1][2][3][4]. Most adverse events occurred during dose-escalation periods, supporting the use of gradual titration protocols [1][2].

Commonly reported effects include:

• Nausea: Frequently reported during early treatment or dose escalation due to appetite-regulating effects on gastric emptying and satiety pathways [1][2]
• Vomiting: Observed in some participants, particularly at higher investigational doses or during rapid dose increases [1][2]
• Diarrhea: Reported in controlled human studies; generally considered manageable with gradual titration [1][2]
• Injection site reactions: Typically mild and transient, including redness or irritation at the subcutaneous injection site [1][3]

Phase 3 REDEFINE trials have not identified serious cardiovascular safety signals to date, though long-term cardiovascular outcomes assessment remains ongoing [3][4]. All discussions of Cagrilintide side effects should be framed within the context of available trial evidence.

Cagrilintide vs. Semaglutide

Cagrilintide and Semaglutide represent distinct receptor classes within investigational and approved metabolic pharmacotherapy. Cagrilintide is an amylin analog targeting CALCR/RAMP receptor complexes involved in satiety signaling and gastric emptying [5], whereas Semaglutide is a GLP-1 receptor agonist approved for obesity and type 2 diabetes management. Phase 2 monotherapy data suggest that Cagrilintide produces approximately a 10.8% reduction in body weight [1], while Semaglutide formulations such as Wegovy have demonstrated approximately a 15% reduction in approved obesity studies. Semaglutide holds FDA approval; Cagrilintide remains under regulatory review as of May 2026.

The more clinically significant comparison is the Phase 3-confirmed CagriSema combination, in which complementary activation of the amylin and GLP-1 pathways produced 20.4% body weight reduction in adults with obesity (REDEFINE 1) [3] and 13.7% in adults with obesity and type 2 diabetes (REDEFINE 2) [4]. The results confirm that the two compounds targeting appetite via distinct central and peripheral mechanisms simultaneously produce additive effects that neither agent achieves alone [3][4], making the combination the primary focus of ongoing regulatory attention. Researchers who choose to buy Semaglutide for comparative protocol work will find its established GLP-1 receptor profile provides a well-characterized reference point alongside Cagrilintide’s amylin mechanism.

Cagrilintide vs. Tirzepatide

The Cagrilintide vs. Tirzepatide comparison centers on differing receptor strategies targeting overlapping metabolic objectives. Cagrilintide functions as an amylin analog activating CALCR/RAMP pathways [5], whereas Tirzepatide is a dual GLP-1/GIP receptor agonist targeting incretin-related satiety and glycemic pathways. Phase 2 monotherapy data place Cagrilintide at approximately 10.8% body weight reduction [1], while Tirzepatide achieved approximately 22% reduction in the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022). Tirzepatide holds FDA approval under the Mounjaro and Zepbound brands; Cagrilintide remains under regulatory review as of May 2026.

Mechanistically, Tirzepatide’s additional GIP receptor activity distinguishes it from Cagrilintide’s amylin-specific pathway [5], and these two approaches represent distinct yet potentially complementary routes in metabolic research. A practitioner might consider Tirzepatide, where incretin-based dual agonism and an established approval profile are priorities, while Cagrilintide may be relevant in investigational contexts exploring amylin-specific appetite modulation or combination strategies with GLP-1 agents. Researchers who choose to buy Tirzepatide for comparative protocol work should review SURMOUNT-1 outcomes alongside the Phase 3 REDEFINE data [3][4] to gain a fuller picture of the current investigational landscape.

Where Can Practitioners Buy Cagrilintide Online?

Cagrilintide is an investigational compound available for purchase only by qualified professionals and is not intended for personal, therapeutic, or clinical use outside authorized research settings. Practitioners looking to order Cagrilintide from a verified research-grade supplier should source only from vendors who can provide verifiable purity documentation, LOT number traceability, and a certificate of analysis for each batch.

Medical Spa Rx’s professional support team offers sourcing guidance and documentation support to help licensed professionals identify qualified suppliers and evaluate wholesale buying options. Practitioners are encouraged to contact Medical Spa Rx’s professional support team directly for guidance on supplier standards, documentation requirements, and research-grade sourcing considerations when looking to buy Cagrilintide online.

FAQs

1. What is Cagrilintide, and what is it used for?

Cagrilintide is a long-acting synthetic amylin analog derived from islet amyloid polypeptide and developed by Novo Nordisk [5]. It activates CALCR/RAMP receptor complexes involved in appetite regulation, delayed gastric emptying, and postprandial suppression of glucagon [5]. Human clinical trials have investigated the compound for weight reduction and management of obesity and type 2 diabetes, both as monotherapy and as part of the CagriSema fixed-dose combination with Semaglutide [1][2][3][4]. A regulatory application was submitted to the FDA in December 2025; as of May 2026, approval has not yet been granted by the FDA, EMA, or TGA.

2. What is the Cagrilintide half-life, and how is it dosed?

The Cagrilintide half-life is approximately seven days, supporting once-weekly subcutaneous administration in investigational protocols [5]. Trial-derived dosing begins at 0.16 mg weekly and is titrated gradually toward higher doses such as 2.4 mg over approximately 16 weeks [1][2]. No FDA-approved prescribing protocol currently exists; all dosing is trial-derived and requires individualized assessment.

3. What are the Cagrilintide benefits and weight loss data?

Phase 2 monotherapy studies reported an approximately 10.8% reduction in body weight over 26 weeks [1]. For the CagriSema combination, landmark Phase 3 trials published in the New England Journal of Medicine in 2025 confirmed a 20.4% mean weight reduction in adults with obesity (REDEFINE 1, Garvey et al.) [3] and a 13.7% mean weight reduction paired with robust HbA1c improvements in adults with obesity and type 2 diabetes (REDEFINE 2, Davies et al.) [4]. All data remain investigational pending formal regulatory approval.

4. How does Cagrilintide compare to Tirzepatide?

Cagrilintide acts through amylin receptor pathways [5], whereas Tirzepatide targets GLP-1 and GIP receptors simultaneously as a dual agonist. Tirzepatide has stronger evidence of maturity and FDA approval, with SURMOUNT-1 data demonstrating approximately 22% weight reduction. Cagrilintide monotherapy shows lower standalone efficacy [1], though Phase 3 REDEFINE data for the CagriSema combination have now demonstrated competitive outcomes in the obesity-without-diabetes population [3].

5. What are the Cagrilintide side effects — is it approved?

Common Cagrilintide side effects reported in Phase 2 and Phase 3 human trials include nausea, vomiting, diarrhea, and mild injection site reactions [1][2][3][4]. Gastrointestinal symptoms are generally managed through gradual dose escalation, consistent with the effects of amylin and GLP-1 classes [1][2]. A regulatory application was submitted to the FDA in December 2025, but as of May 2026, Cagrilintide is not approved by the FDA, EMA, or TGA.

6. Is Cagrilintide a GLP-1 agonist?

No. Cagrilintide activates amylin receptor complexes involving CALCR/RAMP pathways, not GLP-1 receptors [5]. Its mechanism differs substantially from Semaglutide and Tirzepatide, though the pathways are mechanistically complementary. The CagriSema program combines Cagrilintide with Semaglutide to exploit additive effects on appetite regulation and weight reduction by acting on both receptor classes simultaneously [5], a strategy now supported by Phase 3 REDEFINE outcomes [3][4].

Sources

1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. doi:10.1016/S0140-6736(21)01751-7
2. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. doi:10.1016/S0140-6736(23)01163-7
3. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081
4. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659. doi:10.1056/NEJMoa2502082
5. Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.